AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the D’Amico risk of death from prostate cancer after radical prostatectomy. 2004; N Engl J Med 351:125-135. Catalona WJ, Partin AW, Slawin KM, Brawer MK., Flanigan RC, Patel A A et al. multi-centre clinical trial evaluation of free PSA in the differentiation of prostate cancer from benign disease. 1998; 279:1542-1547. J Am Med Assoc Mikolajczyk SD, Millar LS, Wang TJ, Rittenshouse HG, Marks LS, Song W et al. A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. 2000; 60:756-759. Cancer Res Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA Serum et al. prostate- specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. 1993; 270:860-864. J Am Med Assoc Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR Mortality et al. results from a randomised prostate-cancer screening trial. 2009; N Engl J Med 360:1310-1319. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V For the et al. ERSPC Investigators, Screening and prostate-cancer mortality in a randomized European study. 2009; 360:1320-1328. N Engl J Med American Cancer Society Guidelines. Finding cancer early. 2015. Loeb S, Sokoll L, Broyles D, Bangma CH, van Schaik RH, Klee GG Prospective et al. multicenter evaluation of the Beckman Coulter Prostate Health Index using WHO calibration. 2013; 189:1702-1706. J Urol Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, Bangma CH A et al. study of [-2]Pro-Prostate-specific antigen (PSA) in combination with PSA and
D’Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004; 351:125-135. Catalona WJ, Partin AW, Slawin KM, Brawer MK., Flanigan RC, Patel A et al. A multi-centre clinical trial evaluation of free PSA in the differentiation of prostate cancer from benign disease. J Am Med Assoc 1998; 279:1542-1547. Mikolajczyk SD, Millar LS, Wang TJ, Rittenshouse HG, Marks LS, Song W et al. A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. Cancer Res 2000; 60:756-759. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA et al. Serum prostate- specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. J Am Med Assoc 1993; 270:860-864. Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR et al. Mortality results from a randomised prostate-cancer screening trial. N Engl J Med 2009; 360:1310-1319. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V et al. For the ERSPC Investigators, Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360:1320-1328. American Cancer Society Guidelines. Finding cancer early. 2015. Loeb S, Sokoll L, Broyles D, Bangma CH, van Schaik RH, Klee GG et al. Prospective multicenter evaluation of the Beckman Coulter Prostate Health Index using WHO calibration. J Urol 2013; 189:1702-1706. Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, Bangma CH et al. A study of [-2]Pro-Prostate-specific antigen (PSA) in combination with PSA and
13821r1.docx